Much A-Few About Nothing...Time Will Tell for Bioprocessing Hiccup

Research evidence excerpt

Much A-Few About Nothing...Time Will Tell for Bioprocessing Hiccup

USA | Life Science Tools & Diagnostics

Danaher Corp. EquityJulyResearch21, 2026

TARGET | ESTIMATE CHANGEMuch A-Few About Nothing...Time Will Tell for

RATING BUYBioprocessing Hiccup

PRICE $178.10^

The 11% sell-off (one of the largest in 20+ yrs) and debate around reset guide on

bioprocessing are unlikely to assuage tepid LO sentiment into the print. From PRICE TARGET | % TO PT $210.00 ($245.00) | +18%

here, we expect the focus to be on a familiar theme - is the reset on bioprod 52W HIGH-LOW $242.80 - $160.93

overly conservative and is next year (Street +5.5% core) at the right starting FLOAT (%) | ADV MM (USD) 91.1% | 735.80

point? '26 EPS moves higher (albeit less than beat + MASI), although multiple MARKET CAP $126.0B

expansion is unlikely as questions linger on visibility and portfolio TICKER DHR ^Prior trading day's closing price unless otherwise

noted.

Price: Intraday price

Bioprocessing goes sideways quickly. The bioprocessing miss (+LSD vs. +HSD) and lowered '26

outlook (from +HSD to +MSD) was explained as a $100M+ push out of resin orders by a few large

commercial manufacturers, which was framed as timing-related (mix of production schedules and FY (Dec) CHANGE TO JEFe JEF vs CONS

site readiness, expect to recoup in '27) and not indicative of broader demand erosion: consumable 2026 2027 2026 2027

orders were up mid-teens without the customers with higher order growth in resins. However, REV +3% +3% +3% NM

against the backdrop of more bullish intra-Q color and strong demand trends, we acknowledge the EPS +1% NM +1% -1%

narratives around more draconin scenarios, including both resin share loss and longer resin life

times, as we flagged in recent notes here and here.